Avoro Capital Advisors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-255,000
| Closed | -$21M | – | 47 |
|
|
2023
Q2 | $21M | Sell |
255,000
-47,000
| -16% | -$3.87M | 0.28% | 32 |
|
|
2023
Q1 | $31M | Hold |
302,000
| – | – | 0.46% | 27 |
|
|
2022
Q4 | $44.2M | Hold |
302,000
| – | – | 0.66% | 25 |
|
|
2022
Q3 | $51M | Hold |
302,000
| – | – | 0.94% | 19 |
|
|
2022
Q2 | $34.9M | Buy |
302,000
+30,000
| +11% | +$3.47M | 0.69% | 23 |
|
|
2022
Q1 | $27.1M | Hold |
272,000
| – | – | 0.5% | 30 |
|
|
2021
Q4 | $42.3M | Hold |
272,000
| – | – | 0.72% | 22 |
|
|
2021
Q3 | $64.1M | Hold |
272,000
| – | – | 1.01% | 20 |
|
|
2021
Q2 | $92.3M | Hold |
272,000
| – | – | 1.61% | 16 |
|
|
2021
Q1 | $110M | Hold |
272,000
| – | – | 1.9% | 15 |
|
|
2020
Q4 | $181M | Hold |
272,000
| – | – | 3.12% | 11 |
|
|
2020
Q3 | $127M | Buy |
272,000
+12,000
| +5% | +$5.59M | 1.8% | 13 |
|
|
2020
Q2 | $152M | Buy |
+260,000
| New | +$152M | 3.01% | 12 |
|